Responsiveness of EQ-5D and SF-6D in patients with early arthritis: results from the ESPOIR cohort.

Cécile Gaujoux-Viala 1 Anne-Christine Rat 2, 3 Francis Guillemin 2, 3 René-Marc Flipo Patrice Fardellone Pierre Bourgeois 1 Bruno Fautrel 4 Alain Saraux 5, 6, 7
1 Service de Rhumatologie [CHU Pitié-Salpêtrière]
2 APEMAC - Maladies chroniques, santé perçue, et processus d'adaptation
3 Centre d'Investigation Clinique - Epidemiologie Clinique/essais Cliniques Nancy
4 Rhumatologie
5 EA2216 - Immunologie et Pathologie
6 CHU - BREST - Rhumato - CHRU Brest - Service de Rhumatologie
7 CIC - Brest - Centre d'Investigation Clinique
Abstract : OBJECTIVES: The revolution of early aggressive treatments for early arthritis (EA) has fuelled the search for better approaches to establishing their cost-utility ratio. The authors aimed to compare the responsiveness of the EQ-5D and the SF-6D in a large prospective cohort of patients with EA. METHODS: EQ-5D and SF-6D utility measures were assessed in 813 patients with EA over 2 years. Responsiveness was analysed by the standardised response mean (SRM) and effect size between baseline and 6, 12 and 24 months for the entire sample and subgroups by disease evolution (increase or decrease in Disease Activity Score for 28 joints). Bootstrap methods were used to estimate 95% CI. RESULTS: The EQ-5D provided larger absolute mean change estimates with greater variance than the SF-6D, whatever the direction of change. At 12 months, the SF-6D was more sensitive to change with improved condition than the EQ-5D: SRM 0.83 (0.82 to 0.84) versus 0.57 (0.56 to 0.58). In contrast, the EQ-5D was more sensitive to change with deteriorated condition than the SF-6D: SRM -0.20 (-0.23 to -0.18) versus -0.11 (-0.14 to -0.08). Results were similar for 6 and 24 months. CONCLUSIONS: The SF-6D was more responsive than the EQ-5D with improved EA condition. Confidence in the relative cost-effectiveness of two treatments would be better with the SF-6D because of its smaller variance. The SF-6D provided more conservative cost-effectiveness ratios than the EQ-5D and may be more appropriate for trials of biological treatments for patients with EA.
Type de document :
Article dans une revue
Annals of the Rheumatic Diseases, BMJ Publishing Group, 2012, 71 (9), pp.1478-83. 〈10.1136/annrheumdis-2011-200891〉
Liste complète des métadonnées
http://hal.univ-brest.fr/hal-00790812
Contributeur : Ghislaine Calvez <>
Soumis le : jeudi 21 février 2013 - 11:16:17
Dernière modification le : mardi 24 juillet 2018 - 10:16:01

Lien texte intégral

istex

Identifiants

Collections

UNIV-BREST | CGE | UNIV-PARIS5 | IMMUNO | UNIV-LORRAINE | USPC | APEMAC-UL

Citation

Cécile Gaujoux-Viala, Anne-Christine Rat, Francis Guillemin, René-Marc Flipo, Patrice Fardellone, et al.. Responsiveness of EQ-5D and SF-6D in patients with early arthritis: results from the ESPOIR cohort.. Annals of the Rheumatic Diseases, BMJ Publishing Group, 2012, 71 (9), pp.1478-83. 〈10.1136/annrheumdis-2011-200891〉. 〈hal-00790812〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

113

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD